[Thymalin in the combined treatment of patients with chronic lympholeukemia].
Clinico-immunologic indices were studied in patients with the B-variant of chronic lympholeukemia (Stage II) under conditions of inclusion of thymalin in the complex treatment. It was established that use of thymalin in patients with chronic lympholeukemia favoured improvement of the functional activity of lymphoid cells, reduced the time of reaching clinico-hematological remission. Thymalin is indicated in the complex treatment of the above condition.
Babenko
T F
TF
Antonenko
V T
VT
SkuratovskiUi
M F
MF
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000368:Aged; D000917:Antibody Formation / Q000187:drug effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000276:immunology; D008875:Middle Aged; D013951:Thymus Hormones / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D013951:Thymus Hormones; C032805:thymalin
Timalin v kompleksnom lechenii bol'nykh khronicheskim limfoleĭkozom.